Pharmacological Advances for Treatment in Hypertension 2.0
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1369
Special Issue Editor
Interests: antihypertensive; antiatherogenic; cardioprotective; diuretic; lipid-lowering; vasodilator
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Noncommunicable diseases, especially cardiovascular diseases are the main leading cause of morbidity and mortality worldwide. Hypertension is the main aggravating risk factors and can negatively impact the incidence, severity, and clinical course of several types of cardiovascular disease, directly contributing to a complex set of pathological interactions. The relationship between hypertension and other cardiovascular disorders can lead to a higher risk of undesirable outcomes in several patient groups. Moreover, hypertension is also considered an independent determinant of cardiovascular disease. Among the therapeutic options available to treat hypertension, synthetic drugs, as well as herbal medicines, stand out. Medicinal plants have been applied since ancient times and remain a significant therapeutic resource worldwide. Despite their widespread use, many compounds have not experienced careful scientific investigation, whether they are studies of efficacy, toxicity, or drug-to-drug interactions. In addition, there are systematic efforts to discover new therapeutic options for the prevention and treatment of hypertension.
In this Special Issue, we would like to invite investigators to submit preclinical or clinical studies focusing on the pharmacological advances for the treatment of hypertension
We will consider both original research and review articles.
Potential topics include, but are not limited to, the following:
- Animal models of cardiovascular disease associated with hypertension;
- Isolation and characterization of natural products with antihypertensive effects;
- News synthetic drugs useful in the treatment of hypertension;
- Preclinical and clinical trials of synthetic drugs and plant-derived medicines such as antihypertensive agents;
- Systematic or narrative reviews of synthetic drugs and natural products with antihypertensive properties;
- Synergistic effects of synthetic drugs and natural products on hypertension treatment.
Prof. Dr. Arquimedes Gasparotto Junior
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antihypertensive
- cardioprotective
- herbal medicine
- hypertension
- medicinal plants
